Mount Sinai, Pfizer renew research collaboration, building on strong foundation

(The Mount Sinai Hospital / Mount Sinai School of Medicine) The Icahn School of Medicine at Mount Sinai and Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) today announced the renewal of an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid arthritis, Crohn's disease, colitis, heart failure, Alzheimer's disease, and cystic fibrosis.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news